** Shares of insulin delivery device maker Beta Bionics BBNX.O jump as much as 41.2% in their Nasdaq debut
** Stock opens for trading at $22, valuing the Irvine, California-based company at $943.6 mln
** BBNX sold 12 mln shares, 60% more than initially offered, at the top end of its marketed range of $16 and $17 to raise $204 mln
** IPO was twice upsized and follows medical device maker CeriBell's CBLL.O strong debut last year, underscoring a gradual recovery in medtech listings
** BBNX's strong show comes in the aftermath of underwhelming debuts by major IPO candidates including LNG exporter Venture Global VG.N and pork producer Smithfield Foods SFD.O
** BofA Securities, Piper Sandler, Leerink Partners, Stifel and Lake Street were the underwriters for the offering
** Asset manager Wellington Management, an existing Beta shareholder, had agreed to purchase $17 million worth of the company's shares in a concurrent private placement at the IPO price
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。